Wellington Management Group LLP lifted its holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report) by 110.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 170,228 shares of the company’s stock after buying an additional 89,481 shares during the quarter. Wellington Management Group LLP’s holdings in Tango Therapeutics were worth $1,685,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the business. Boxer Capital LLC boosted its holdings in shares of Tango Therapeutics by 15.1% in the fourth quarter. Boxer Capital LLC now owns 8,198,642 shares of the company’s stock valued at $81,167,000 after buying an additional 1,075,000 shares during the period. Vanguard Group Inc. lifted its position in Tango Therapeutics by 7.2% in the 3rd quarter. Vanguard Group Inc. now owns 2,939,843 shares of the company’s stock valued at $33,103,000 after acquiring an additional 197,624 shares in the last quarter. RTW Investments LP acquired a new position in Tango Therapeutics in the 4th quarter worth $19,471,000. Adage Capital Partners GP L.L.C. increased its holdings in Tango Therapeutics by 47.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,754,852 shares of the company’s stock worth $19,760,000 after purchasing an additional 564,971 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Tango Therapeutics by 3,247.3% in the 3rd quarter. Invesco Ltd. now owns 774,738 shares of the company’s stock valued at $8,724,000 after purchasing an additional 751,593 shares during the period. 78.99% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other news, insider Mva Investors, Llc sold 75,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $7.43, for a total value of $557,250.00. Following the completion of the sale, the insider now directly owns 618,524 shares of the company’s stock, valued at $4,595,633.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 198,000 shares of company stock valued at $1,469,970 over the last 90 days. 6.20% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Check Out Our Latest Research Report on TNGX
Tango Therapeutics Trading Up 4.9 %
NASDAQ:TNGX opened at $9.00 on Tuesday. The stock has a market capitalization of $961.65 million, a PE ratio of -7.96 and a beta of 0.83. Tango Therapeutics, Inc. has a 1-year low of $2.88 and a 1-year high of $13.03. The firm has a fifty day simple moving average of $7.85 and a 200 day simple moving average of $9.29.
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). The firm had revenue of $6.47 million during the quarter, compared to the consensus estimate of $7.13 million. Tango Therapeutics had a negative net margin of 299.88% and a negative return on equity of 44.35%. On average, equities analysts predict that Tango Therapeutics, Inc. will post -1.31 earnings per share for the current fiscal year.
Tango Therapeutics Profile
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Further Reading
- Five stocks we like better than Tango Therapeutics
- Following Congress Stock Trades
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What is the Dow Jones Industrial Average (DJIA)?
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Want to see what other hedge funds are holding TNGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report).
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.